Literature DB >> 7624387

Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use.

M Wolfersdorf1, T Barg, F König, M Leibfarth, I Grünewald.   

Abstract

The combination of antidepressive and antipsychotic (neuroleptic) medication is often used in the psychopharmacological treatment of delusional depression. In most studies of the treatment of delusional depression, tricyclic antidepressants have been used, and very little has been written about experience with SSRIs such as fluvoxamine, fluoxetine, or paroxetine. This paper therefore presents the preliminary findings of an open clinical study in which 14 delusional depressed inpatients, consecutively admitted to our Depression Unit, were given paroxetine combined with either zotepine or haloperidol. It was possible to observe a significantly impressive decline in the HAMD (24-item version) total score, of so-called delusional items (HAMD subscore of items 2, 17, 18, 20, 23, 24) and of the subscore of remaining HAMD items over 21 treatment days. There were no unusual side-effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7624387     DOI: 10.1055/s-2007-979589

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  5 in total

Review 1.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Paroxetine: a review.

Authors:  M Bourin; P Chue; Y Guillon
Journal:  CNS Drug Rev       Date:  2001

Review 3.  Clinically significant interactions of psychotropic agents with antipsychotic drugs.

Authors:  M C Meyer; R J Baldessarini; D C Goff; F Centorrino
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

4.  Olanzapine and fluoxetine combination in severe or resistant depression.

Authors:  R M Haridas; S R Parkar; Ram Ghulam; Gautam Amin; K G Thombre; A Srivastava; N Bhuvaneshwari; S Telang; Monika Obrah; Nandkishore Toraskar; R K Jalali; Kiran V Marthak
Journal:  Indian J Psychiatry       Date:  2003-10       Impact factor: 1.759

5.  Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study.

Authors:  A Gabriel
Journal:  Neuropsychiatr Dis Treat       Date:  2013-04-12       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.